{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T12:39:19Z","timestamp":1793104759049,"version":"4.5.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","phiro.science","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Physics and Imaging in Radiation Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.phro.2026.101070","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T23:46:21Z","timestamp":1787701581000},"page":"101070","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Impact of dynamic beam delivery of intensity-modulated radiation therapy and volumetric modulated arc therapy on circulating immune cell exposure in glioma"],"prefix":"10.1016","volume":"41","author":[{"given":"Abdelkhalek","family":"Hammi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadya","family":"Shusharina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Gkika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youness","family":"Nour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phro.2026.101070_bb0005","article-title":"Glioblastoma: clinical presentation, diagnosis, and management","volume":"374","author":"McKinnon","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.phro.2026.101070_bb0010","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/neuonc\/nox158","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2010\u20132014","author":"Ostrom","year":"2017","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.phro.2026.101070_bb0015","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s11060-011-0749-4","article-title":"Glioblastoma survival in the United States before and during the temozolomide era","volume":"107","author":"Johnson","year":"2012","journal-title":"J Neuro-Oncol"},{"key":"10.1016\/j.phro.2026.101070_bb0020","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41571-020-00447-z","article-title":"EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood","volume":"18","author":"Weller","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.phro.2026.101070_bb0025","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/S1470-2045(17)30517-X","article-title":"Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial","volume":"18","author":"Weller","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.phro.2026.101070_bb0030","doi-asserted-by":"crossref","first-page":"4776","DOI":"10.1158\/1078-0432.CCR-16-0506","article-title":"A Cancer Research UK first time in human phase I trial of IMA950 (novel multipeptide therapeutic vaccine) in patients with newly diagnosed glioblastoma","volume":"22","author":"Rampling","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.phro.2026.101070_bb0035","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1093\/neuonc\/nou348","article-title":"A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study","volume":"17","author":"Schuster","year":"2015","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.phro.2026.101070_bb0040","doi-asserted-by":"crossref","first-page":"4062","DOI":"10.1158\/1078-0432.CCR-15-0428","article-title":"Bioactivity and safety of IL13R\u03b12-redirected chimeric antigen receptor CD8+ T cells in patients with recurrent glioblastoma","volume":"21","author":"Brown","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.phro.2026.101070_bb0045","doi-asserted-by":"crossref","first-page":"7003","DOI":"10.18632\/oncotarget.12273","article-title":"Phase III randomized trial of autologous cytokine-induced killer cell immunotherapy for newly diagnosed glioblastoma in Korea","volume":"8","author":"Kong","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.phro.2026.101070_bb0050","doi-asserted-by":"crossref","first-page":"5473","DOI":"10.1158\/1078-0432.CCR-11-0774","article-title":"Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide","volume":"17","author":"Grossman","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.phro.2026.101070_bb0055","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.6004\/jnccn.2015.0151","article-title":"Survival in patients with severe lymphopenia following treatment with radiation and chemotherapy for newly diagnosed solid tumors","volume":"13","author":"Grossman","year":"2015","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.phro.2026.101070_bb0060","doi-asserted-by":"crossref","first-page":"114268","DOI":"10.18632\/oncotarget.23217","article-title":"Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors","volume":"8","author":"Diehl","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.phro.2026.101070_bb0065","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.ijrobp.2015.04.005","article-title":"Clinical and dosimetric predictors of acute severe lymphopenia during radiation therapy and concurrent temozolomide for high-grade glioma","volume":"92","author":"Huang","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.phro.2026.101070_bb0070","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s11060-019-03167-2","article-title":"Clinical observation of lymphopenia in patients with newly diagnosed glioblastoma","volume":"143","author":"Kim","year":"2019","journal-title":"J Neuro-Oncol"},{"key":"10.1016\/j.phro.2026.101070_bb0075","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/neuros\/nyz198","article-title":"Radiotherapy, lymphopenia, and host immune capacity in glioblastoma: a potentially actionable toxicity associated with reduced efficacy of radiotherapy","volume":"85","author":"Kleinberg","year":"2019","journal-title":"Neurosurgery"},{"key":"10.1016\/j.phro.2026.101070_bb0080","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1093\/neuonc\/noaa106","article-title":"Glioblastoma in adults: a Society for Neuro-Oncology and European Society of Neuro-Oncology consensus review on current management and future directions","volume":"22","author":"Wen","year":"2020","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.phro.2026.101070_bb0085","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1200\/JCO.22.00164","article-title":"NRG Oncology\/RTOG1205: a randomized phase II trial of concurrent bevacizumab and reirradiation versus bevacizumab alone as treatment for recurrent glioblastoma","volume":"41","author":"Tsien","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.phro.2026.101070_bb0090","doi-asserted-by":"crossref","DOI":"10.3390\/life12020195","article-title":"Multi-planar VMAT plans for high-grade glioma and glioblastoma targeting the hypothalamic-pituitary axis sparing","volume":"12","author":"Cheung","year":"2022","journal-title":"Life"},{"key":"10.1016\/j.phro.2026.101070_bb0095","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.radonc.2019.06.031","article-title":"Deep learning derived tumor infiltration maps for personalized target definition in glioblastoma radiotherapy","volume":"138","author":"Peeken","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.phro.2026.101070_bb0100","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1007\/s11604-023-01434-x","article-title":"The need of radiotherapy optimization for glioblastomas considering immune responses","volume":"41","author":"Nishioka","year":"2023","journal-title":"Jpn J Radiol"},{"key":"10.1016\/j.phro.2026.101070_bb0105","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s11060-015-2037-1","article-title":"Association between treatment-related lymphopenia and overall survival in elderly patients with newly diagnosed glioblastoma","volume":"127","author":"Mendez","year":"2016","journal-title":"J Neuro-Oncol"},{"key":"10.1016\/j.phro.2026.101070_bb0110","doi-asserted-by":"crossref","first-page":"164001","DOI":"10.1088\/1361-6560\/ac16ea","article-title":"HEDOS\u2014a computational tool to assess radiation dose to circulating blood cells during external beam radiotherapy based on whole-body blood flow simulations","volume":"66","author":"Shin","year":"2021","journal-title":"Phys Med Biol"},{"key":"10.1016\/j.phro.2026.101070_bb0115","doi-asserted-by":"crossref","first-page":"224","DOI":"10.2307\/3577549","article-title":"Radiosensitivity of CD4- or CD8-positive human T-lymphocytes by an in vitro colony formation assay","volume":"123","author":"Nakamura","year":"1990","journal-title":"Radiat Res"},{"key":"10.1016\/j.phro.2026.101070_bb0120","doi-asserted-by":"crossref","first-page":"140","DOI":"10.3109\/07357907.2012.762780","article-title":"The etiology of treatment-related lymphopenia in patients with malignant gliomas: modeling radiation dose to circulating lymphocytes explains clinical observations and suggests methods of modifying the impact of radiation on immune cells","volume":"31","author":"Yovino","year":"2013","journal-title":"Cancer Investig"},{"key":"10.1016\/j.phro.2026.101070_bb0125","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/j.ijrobp.2004.12.085","article-title":"Primary brain tumors treated with steroids and radiotherapy: low CD4 counts and risk of infection","volume":"62","author":"Hughes","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.phro.2026.101070_bb0130","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.semradonc.2019.12.003","article-title":"Lymphocyte-sparing radiotherapy: the rationale for protecting lymphocyte-rich organs when combining radiotherapy with immunotherapy","volume":"30","author":"Lambin","year":"2020","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.phro.2026.101070_bb0135","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.phro.2026.101070_bb0140","doi-asserted-by":"crossref","DOI":"10.1088\/1361-6560\/ab6c41","article-title":"4D blood flow model for dose calculation to circulating blood and lymphocytes","volume":"65","author":"Hammi","year":"2020","journal-title":"Phys Med Biol"},{"key":"10.1016\/j.phro.2026.101070_bb0145","doi-asserted-by":"crossref","DOI":"10.1088\/1361-6560\/acdcdc","article-title":"4D dosimetric-blood flow model: impact of prolonged fraction delivery times of IMRT on the dose to the circulating lymphocytes","volume":"68","author":"Hammi","year":"2023","journal-title":"Phys Med Biol"},{"key":"10.1016\/j.phro.2026.101070_bb0150","doi-asserted-by":"crossref","DOI":"10.1088\/1361-6560\/ad144e","article-title":"FLASH radiotherapy sparing effect on the circulating lymphocytes in pencil beam scanning proton therapy: impact of hypofractionation and dose rate","volume":"69","author":"Galts","year":"2024","journal-title":"Phys Med Biol"},{"key":"10.1016\/j.phro.2026.101070_bb0155","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.ijrobp.2009.03.013","article-title":"A comparison of volumetric modulated arc therapy and conventional intensity-modulated radiotherapy for frontal and temporal high-grade gliomas","volume":"76","author":"Shaffer","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.phro.2026.101070_bb0160","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.radonc.2010.01.011","article-title":"Single arc volumetric modulated arc therapy of head and neck cancer","volume":"95","author":"Bertelsen","year":"2010","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.phro.2026.101070_bb0165","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ijrobp.2009.05.038","article-title":"Volumetric modulated arc therapy improves dosimetry and reduces treatment time compared with conventional intensity-modulated radiotherapy for locoregional radiotherapy of left-sided breast cancer and internal mammary nodes","volume":"76","author":"Popescu","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.phro.2026.101070_bb0170","series-title":"Glioma Image Segmentation for Radiotherapy: RT Targets, Barriers to Cancer Spread, and Organs at Risk (GLIS-RT) [Data Set]","author":"Shusharina","year":"2021"},{"issue":"3\u20134","key":"10.1016\/j.phro.2026.101070_bb0175","article-title":"Basic anatomical and physiological data for use in radiological protection: reference values","volume":"32","author":"International Commission on Radiological Protection","year":"2002","journal-title":"Ann ICRP"},{"key":"10.1016\/j.phro.2026.101070_bb0180","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1161\/01.CIR.1.1.76","article-title":"Determination of blood volume in the heart and lungs and the cardiac output through the injection of radiophosphorus","volume":"1","author":"Nylin","year":"1950","journal-title":"Circulation"},{"key":"10.1016\/j.phro.2026.101070_bb0185","doi-asserted-by":"crossref","DOI":"10.1088\/1361-6560\/ad69f9","article-title":"Inter-subject cerebrovascular variability: a source of uncertainty for dose calculation to circulating blood cells for glioblastoma patients treated with modern radiotherapy techniques","volume":"69","author":"Hammi","year":"2024","journal-title":"Phys Med Biol"},{"key":"10.1016\/j.phro.2026.101070_bb0190","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.mri.2012.05.001","article-title":"3D slicer as an image computing platform for the quantitative imaging network","volume":"30","author":"Fedorov","year":"2012","journal-title":"Magn Reson Imaging"},{"key":"10.1016\/j.phro.2026.101070_bb0195","first-page":"23","article-title":"CTIM-25. A randomized phase 3 study of nivolumab or placebo combined with radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma with methylated MGMT promoter: CheckMate 548","author":"Weller","year":"2021","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.phro.2026.101070_bb0200","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.TPS2079","article-title":"A randomized, phase 3, open-label study of nivolumab versus temozolomide in combination with radiotherapy in adult patients with newly diagnosed, O6-methylguanine DNA methyltransferase-unmethylated glioblastoma: CheckMate-498","volume":"34","author":"Sampson","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.phro.2026.101070_bb0205","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ijrobp.2018.01.069","article-title":"Effect of radiation treatment volume reduction on lymphopenia in patients receiving chemoradiotherapy for glioblastoma","volume":"101","author":"Rudra","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.phro.2026.101070_bb0210","article-title":"Systematic review and pooled analysis of the impact of treatment-induced lymphopenia on survival of glioblastoma patients","volume":"19","author":"Saeed","year":"2024","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.phro.2026.101070_bb0215","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1093\/neuonc\/noaa182","article-title":"Proton therapy reduces the likelihood of high-grade radiation-induced lymphopenia in glioblastoma patients: phase II randomized study of protons versus photons","volume":"23","author":"Mohan","year":"2021","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.phro.2026.101070_bb0220","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-021-08004-2","article-title":"The predictive value of absolute lymphocyte counts on tumor progression and pseudoprogression in patients with glioblastoma","volume":"21","author":"Xi","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.phro.2026.101070_bb0225","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s00066-021-01855-5","article-title":"Association between treatment-related lymphopenia and survival in glioblastoma patients following postoperative chemoradiotherapy","volume":"198","author":"Mapelli","year":"2022","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.phro.2026.101070_bb0230","article-title":"Nomogram for radiation-induced lymphopenia in patients receiving intensity-modulated radiotherapy-based chemoradiation therapy for newly diagnosed glioblastoma: a multi-institutional study","volume":"47","author":"Kim","year":"2024","journal-title":"Clin Transl Radiat Oncol"}],"container-title":["Physics and Imaging in Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405631626001703?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405631626001703?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T12:30:16Z","timestamp":1793104216000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405631626001703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":46,"alternative-id":["S2405631626001703"],"URL":"https:\/\/doi.org\/10.1016\/j.phro.2026.101070","relation":{},"ISSN":["2405-6316"],"issn-type":[{"value":"2405-6316","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of dynamic beam delivery of intensity-modulated radiation therapy and volumetric modulated arc therapy on circulating immune cell exposure in glioma","name":"articletitle","label":"Article Title"},{"value":"Physics and Imaging in Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phro.2026.101070","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Society of Radiotherapy & Oncology.","name":"copyright","label":"Copyright"}],"article-number":"101070"}}